Tech Company Financing Transactions
CODA Biotherapeutics Funding Round
CODA Biotherapeutics, based in San Francisco, scored $15 million in funding from Astellas Venture Capital, MPM Capital and Versant Ventures.
Transaction Overview
Company Name
Announced On
11/7/2019
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Proceeds Purpose
The new funding will push Coda's lead programs toward the clinic--potentially sometime in 2021.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 2nd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform for the treatment of many disorders and diseases. The company is using a revolutionary chemogenetics-based technology to modulate the activity of pathological cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Narachi
Vice President
Steven Dodson
VP - R & D
Orion Keifer
Browse more venture capital transactions:
Prev: 11/7/2019: Neural Magic venture capital transaction
Next: 11/7/2019: HMBradley venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record funding rounds that are announced publicly. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs